Perioperative immune-based treatment for cisplatin-eligible muscle-invasive bladder cancer: a meta-analysis of randomized controlled trials.
Immune-based treatments before and after bladder cancer surgery show promise, though researchers still need to identify which approach works best for which patients.
This PubMed-indexed study examined pURPOSE: Perioperative immune-based strategies are redefining the treatment landscape of muscle-invasive bladder cancer, but their overall benefit and subgroup effects remain incompletely characterized. The abstract reports however, the two regimens should not be considered interchangeable, and the optimal regimen and patients deriving the greatest benefit remain uncertain.
What the study was
- Study design
- Systematic Review
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Critical reviews in oncology/hematology
Why it surfaced
Conservative triage based on the PubMed abstract: systematic review with direct watchlist relevance; score reflects metadata and abstract-level evidence only.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.